NEW YORK – Nonprofit organization Friends of Cancer Research (Friends) on Wednesday unveiled a new public-private research partnership to harmonize the use of homologous recombination deficiency (HRD) as a biomarker to guide certain treatment types in cancer patients.
Currently, there is no standardized way to define, measure, and report HRD, a complex biomarker that has shown promise in identifying patients with certain cancers who are more likely to benefit from PARP inhibitors and drugs in development that target cells with DNA repair defects.